National position statement: diagnosis and treatment of tuberculosis infection
DOI:
https://doi.org/10.33321/cdi.2026.50.067Keywords:
tuberculosis, tuberculosis infection, latent tuberculosis infection, diagnosis, treatment, national position statement, TB, TBIAbstract
This updated National position statement replaces the National Position Statement for the Management of Latent Tuberculosis Infection (2017) and incorporates current evidence and guidance for the diagnosis and treatment of tuberculosis infection (TBI) in Australia. It provides nationally consistent recommendations on the diagnosis, risk assessment and management of TBI , including updating terminology, testing approaches, priority populations for screening and treatment, and recommended preventive treatment options.
Downloads
References
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi: https://doi.org/10.1371/journal.pmed.1002152.
Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn JA et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845–55. doi: https://doi.org/10.1038/nrmicro2236.
Bright A, Denholm JT, Coulter C, Waring J, Stapledon R. Tuberculosis notifications in Australia, 2015–2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.88.
Globan M, Lavender C, Leslie D, Brown L, Denholm J, Raios K et al. Molecular epidemiology of tuberculosis in Victoria, Australia, reveals low level of transmission. Int J Tuberc Lung Dis. 2016;20(5):652–8. doi: https://doi.org/10.5588/ijtld.15.0437.
Gurjav U, Outhred AC, Jelfs P, McCallum N, Wang Q, Hill-Cawthorne GA et al. Whole genome sequencing demonstrates limited transmission within identified Mycobacterium tuberculosis clusters in New South Wales, Australia. PLoS One. 2016;11(10):e0163612. doi: https://doi.org/10.1371/journal.pone.0163612.
World Health Organization (WHO). Sixty-seventh World Health Assembly, Geneva, 19–24 May 2014. Geneva: WHO; 2014. Available from: https://apps.who.int/gb/ebwha/pdf_files/wha67-rec1/a67_2014_rec1-en.pdf.
Denholm JT, McBryde ES. Can Australia eliminate TB? Modelling immigration strategies for reaching MDG targets in a low transmission setting. Aust N Z J Public Health. 2014;38(1):78–82. doi: https://doi.org/10.1111/1753-6405.12161.
Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES et al. Risk of active tuberculosis in the five years following infection …15%? Chest. 2016;149 (2):516–25. doi: https://doi.org/10.1016/j.chest.2015.11.017.
WHO. WHO operational handbook on tuberculosis: module 3: diagnosis tests for tuberculosis infection. Geneva: WHO; 30 September 2022. Available from: https://www.who.int/publications/iem/9789240058347.
National Tuberculosis Advisory Committee. Position statement on interferon-γ release assays in the detection of latent tuberculosis infection. Commun Dis Intell Q Rep. 2012;36(1);125–31. doi: https://doi.org/10.33321/cdi.2012.36.8.
Turner NA, Ahmed A, Haley CA, Starke JR, Stout JE. Use of interferon-gamma release assays in children < 2 years old. J Pediatric Infect Dis Soc. 2023;12(8):481–5. doi: https://doi.org/10.1093/jpids/piad053.
Tuberculosis Coalition for Technical Assistance (TCTA). International Standards for Tuberculosis Care (ISTC). The Hague: TCTA; 15 July 2006. Available from: https://cdn.who.int/media/docs/default-source/documents/tuberculosis/istc_reportd3b3091a-acdb-487d-b2b0-83a3781ddcf6.pdf.
Dale KD, Trauer J, Dodd PJ Houben RMGJ, Denholm JT. Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia. Eur Respir J. 2018;52(6);1801218. doi: https://doi.org/10.1183/13993003.01218-2018.
Waring J, National Tuberculosis Advisory Committee. National Tuberculosis Advisory Committee guideline: management of tuberculosis risk in healthcare workers in Australia. Commun Dis Intell Q Rep. 2017;41(3)E199–203. doi: https://doi.org/10.33321/cdi.2017.41.28.
WHO. WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: WHO; 9 September 2024. Available from: https://www.who.int/publications/i/item/9789240097773.
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53. doi: https://doi.org/10.1056/NEJMoa1714283.
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2536088/.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847–50. Available from: https://www.ingentaconnect.com/content/iuatld/ijtld/1999/00000003/00000010/art00001.
Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;1999(2):CD001363. doi: https://doi.org/10.1002/14651858.CD001363.
Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827–30. doi: https://doi.org/10.1164/arrd.1979.119.5.827.
Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117(6):991–1001. doi: https://doi.org/10.1164/arrd.1978.117.6.991.
Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–18. doi: https://doi.org/10.1001/jama.281.11.1014.
Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670–6. doi: https://doi.org/10.1086/427802.
WHO. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: WHO; 9 September 2024. Available from: https://www.who.int/publications/i/item/9789240096196.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. doi: https://doi.org/10.1056/NEJMoa1104875.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20. doi: https://doi.org/10.1056/NEJMoa1005136.
United States Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–3. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm.
Fox G, Nhung NV, Binh NC, Hoa NB, Garden FL, Benedetti A et al. Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam. N Engl J Med. 2024;391(24):2304–14. doi: https://doi.org/10.1056/NEJMoa2314325.
Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J et al. Levofloxacin preventive treatment in children exposed to MDR tuberculosis. N Engl J Med. 2024;39124:2315–26. doi: https://doi.org/10.1056/NEJMoa2314318.
Duong T, Brigden J, Schaaf HS, Garden F, Marais BJ, Nguyen TA et al. A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis. NEJM Evid. 2025;4(1):EVIDoa2400190. doi: https://doi.org/10.1056/EVIDoa2400190.
Street A, McBryde E, Denholm J, Eisen D. Management of Tuberculosis: a handbook for clinicians. Melbourne: Victorian Infectious Diseases Service; 2012. Available from: https://researchonline.jcu.edu.au/51444/.
Published
How to Cite
License
Copyright (c) 2026 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
